INTRODUCTION: Approximately 80% of children currently survive 5 years following diagnosis of their cancer. Studies based on limited data have implicated certain cancer therapies in the development of ocular sequelae in these survivors. PROCEDURE: The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort study investigating health outcomes of 5+ year survivors diagnosed and treated between 1970 and 1986 compared to a sibling cohort. The baseline questionnaire included questions about the first occurrence of six ocular conditions. Relative risks (RR) and 95% confidence intervals (CI) were calculated from responses of 14,362 survivors and 3,901 siblings. RESULTS: Five or more years from the diagnosis, survivors were at increased risk of cataracts (RR: 10.8; 95% CI: 6.2-18.9), glaucoma (RR: 2.5; 95% CI: 1.1-5.7), legal blindness (RR: 2.6; 95% CI: 1.7-4.0), double vision (RR: 4.1; 95% CI: 2.7-6.1), and dry eyes (RR: 1.9; 95% CI: 1.6-2.4), when compared to siblings. Dose of radiation to the eye was significantly associated with risk of cataracts, legal blindness, double vision, and dry eyes, in a dose-dependent manner. Risk of cataracts were also associated with radiation 3,000+ cGy to the posterior fossa (RR: 8.4; 95% CI: 5.0-14.3), temporal lobe (RR: 9.4; 95% CI: 5.6-15.6), and exposure to prednisone (RR: 2.3; 95% CI: 1.6-3.4). CONCLUSIONS: Childhood cancer survivors are at risk of developing late occurring ocular complications, with exposure to glucocorticoids and cranial radiation being important determinants of increased risk. Long-term follow-up is needed to evaluate potential progression of ocular deficits and impact on quality of life. Copyright 2009 Wiley-Liss, Inc.
INTRODUCTION: Approximately 80% of children currently survive 5 years following diagnosis of their cancer. Studies based on limited data have implicated certain cancer therapies in the development of ocular sequelae in these survivors. PROCEDURE: The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort study investigating health outcomes of 5+ year survivors diagnosed and treated between 1970 and 1986 compared to a sibling cohort. The baseline questionnaire included questions about the first occurrence of six ocular conditions. Relative risks (RR) and 95% confidence intervals (CI) were calculated from responses of 14,362 survivors and 3,901 siblings. RESULTS: Five or more years from the diagnosis, survivors were at increased risk of cataracts (RR: 10.8; 95% CI: 6.2-18.9), glaucoma (RR: 2.5; 95% CI: 1.1-5.7), legal blindness (RR: 2.6; 95% CI: 1.7-4.0), double vision (RR: 4.1; 95% CI: 2.7-6.1), and dry eyes (RR: 1.9; 95% CI: 1.6-2.4), when compared to siblings. Dose of radiation to the eye was significantly associated with risk of cataracts, legal blindness, double vision, and dry eyes, in a dose-dependent manner. Risk of cataracts were also associated with radiation 3,000+ cGy to the posterior fossa (RR: 8.4; 95% CI: 5.0-14.3), temporal lobe (RR: 9.4; 95% CI: 5.6-15.6), and exposure to prednisone (RR: 2.3; 95% CI: 1.6-3.4). CONCLUSIONS:Childhood cancer survivors are at risk of developing late occurring ocular complications, with exposure to glucocorticoids and cranial radiation being important determinants of increased risk. Long-term follow-up is needed to evaluate potential progression of ocular deficits and impact on quality of life. Copyright 2009 Wiley-Liss, Inc.
Authors: K Scott Baker; James G Gurney; Kirsten K Ness; Ravi Bhatia; Stephen J Forman; Liton Francisco; Philip B McGlave; Leslie L Robison; David S Snyder; Daniel J Weisdorf; Smita Bhatia Journal: Blood Date: 2004-06-01 Impact factor: 22.113
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 50.717
Authors: Ann C Mertens; Qi Liu; Joseph P Neglia; Karen Wasilewski; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Yutaka Yasui Journal: J Natl Cancer Inst Date: 2008-09-23 Impact factor: 11.816
Authors: J S Kornerup; N P Brodin; T Björk-Eriksson; C Birk Christensen; A Kiil-Berthelsen; M C Aznar; C Hollensen; E Markova; P Munck Af Rosenschöld Journal: Br J Radiol Date: 2014-12-12 Impact factor: 3.039
Authors: Peter M K de Blank; Michael J Fisher; Lu Lu; Wendy M Leisenring; Kirsten K Ness; Charles A Sklar; Marilyn Stovall; Chris Vukadinovich; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Cancer Date: 2016-01-11 Impact factor: 6.860
Authors: Aniket Saha; Christina G Salley; Preeti Saigal; Linda Rolnitzky; Judith Goldberg; Suzanne Scott; Randal Olshefski; Juliette Hukin; Stephen A Sands; Jonathan Finlay; Sharon L Gardner Journal: Pediatr Blood Cancer Date: 2014-05-01 Impact factor: 3.167
Authors: Gabriel Chodick; Alice J Sigurdson; Ruth A Kleinerman; Charles A Sklar; Wendy Leisenring; Ann C Mertens; Marilyn Stovall; Susan A Smith; Rita E Weathers; Lene H S Veiga; Leslie L Robison; Peter D Inskip Journal: Radiat Res Date: 2016-03-29 Impact factor: 2.841